Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Area of Science:

• Cardiovascular disease research
• Hepatology
• Metabolic syndrome studies

Background:

• Hepatic steatosis (HS) is a prevalent liver disorder and an independent predictor of cardiovascular disease.
• The combination of HS and metabolic syndrome (MetS) may synergistically impact low-density lipoprotein (LDL) particle size.
• Understanding these relationships is crucial for cardiovascular risk assessment.

Purpose of the Study:

• To investigate the association between hepatic steatosis (HS), metabolic syndrome (MetS), and low-density lipoprotein (LDL) particle size.
• To evaluate the impact of HS alone and in combination with MetS on carotid atherosclerosis markers.
• To determine if these associations persist after adjusting for potential confounders.

Main Methods:

• 274 healthy workers underwent ultrasonographic diagnosis of HS and carotid intima-media thickness (IMT) and plaque.
• Metabolic syndrome (MetS) was diagnosed using ATP III criteria.
• LDL particle size and subfractions (LDL I and LDL III) were measured using density gradient ultracentrifugation.

Main Results:

• Subjects with HS alone constituted 30.7%, while those with HS and MetS were 16.8%.
• Significant negative correlations were observed between LDL peak particle size and carotid mean IMTs.
• HS was associated with decreased LDL peak particle size and LDL I, with the most pronounced effects seen in subjects with both HS and MetS. LDL III also showed independent associations.

Conclusions:

• Hepatic steatosis (HS) alone is more common than HS combined with metabolic syndrome (MetS) in the general population.
• Individuals with HS alone exhibited intermediate levels of LDL particle size and carotid atherosclerosis compared to controls and those with both HS and MetS.
• These findings highlight the compounded risk of cardiovascular atherosclerosis when HS is present with MetS.